HLTF

Across TCGA pan-cancer cohorts, HLTF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HLTF data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HLTF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HLTF expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where HLTF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.865	0.963	.006	52	view →
HNSC	DFS	Median	III,IV	0.676	0.896	.009	5	view →
LUAD	OS	Median	III,IV	0.826	0.267	.036	4	view →
LSCC	DFS	Median	All	0.495	0.831	.036	4	view →
PDAC	OS	Tertile	III,IV	1.000	0.600	.049	1	view →
GBM	OS	Tertile	All	0.758	0.894	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HLTF–CCRCC (DFS)

Open the CCRCC breakdown →